Immune normalization strategy against suboptimal health status: safe and efficacious therapy using mixed-natural killer cells
Li Y, Harunori O, Fu S, Xing F, Wu H, Wang J, Chen A, Ren X, Peng D, Ling X, Shi M, Wu H. Immune normalization strategy against suboptimal health status: safe and efficacious therapy using mixed-natural killer cells. Aging 2021, 13: 20131-20148. PMID: 34461606, PMCID: PMC8436936, DOI: 10.18632/aging.203279.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAgedAntigensCD3 ComplexCD56 AntigenCD8-Positive T-LymphocytesCell Culture TechniquesHealth StatusHumansImmune SystemImmunityImmunotherapyKiller Cells, NaturalLeukocytes, MononuclearLymphomaMiddle AgedNeoplasmsPancreatic NeoplasmsProgrammed Cell Death 1 ReceptorReceptors, IgGT-Lymphocytes, Helper-InducerTreatment OutcomeConceptsPeripheral blood mononuclear cellsPD-1<sup>+</sup> T cellsProgrammed cell death protein 1Sub-healthy individualsNKM cellsImmune normalizationT cellsCD8<sup>+</sup>PD-1<sup>+</sup> T cellsCancer patientsCell death protein 1Proportion of NK cellsProportion of T helper cellsPeripheral immune systemT helper cellsBlood mononuclear cellsPotential clinical applicationsMalignant lymphomaNK cellsAdjuvant treatmentKiller cellsPancreatic cancerMononuclear cellsEfficacious therapyCancer preventionSide effects